早期未分化关节炎三种治疗策略比较:ICEa随机临床试验
这项多中心单盲随机对照试验将早期未分化关节炎患者随机分为NSAIDs、甲氨蝶呤或巴瑞替尼三组,均先接受糖皮质激素注射。3个月时巴瑞替尼组DAS改善显著优于NSAIDs组,甲氨蝶呤组数值相似但未达统计学显著。12个月时三组疾病活动度无显著差异,总体结局良好。
要点
- 早期未分化关节炎患者3个月时巴瑞替尼的DAS改善显著优于NSAIDs。
- 甲氨蝶呤组3个月DAS改善数值上接近巴瑞替尼但未达统计学显著。
- 12个月时三组DAS无显著差异,总体结局良好且严重不良事件发生率低。
核心结论
- 在早期未分化关节炎患者中,与NSAIDs相比,早期DMARD治疗可在3个月内带来更大的疾病活动度改善,其中巴瑞替尼达到统计学显著。
- 12个月时三组疾病活动度无显著差异,总体结局良好。
研究设计与样本
- 诱导早期关节炎治愈研究为3个月多中心单盲随机对照试验,随后9个月观察期。
- 纳入早期未使用过DMARD的未分化关节炎患者,关节炎≥2个关节且不符合ACR/EULAR 2010类风湿关节炎标准。
- 所有患者接受40 mg关节腔内或肌内糖皮质激素注射后,按1:1:1随机分为NSAIDs标准日剂量组(n=29)、甲氨蝶呤15 mg/周增至25 mg/周组(n=28)或巴瑞替尼4 mg/日组(n=28)。
- 主要终点为3个月时DAS(44/53关节)改善,采用协方差分析并校正基线DAS。
主要发现
- 3个月时巴瑞替尼组较NSAIDs组DAS校正平均变化为-0.52(95%CI -0.93至-0.11;p=0.01),差异显著。
- 甲氨蝶呤组较NSAIDs组DAS校正平均变化为-0.39(95%CI -0.84至0.06;p=0.09),未达统计学显著。
- 12个月时DAS在甲氨蝶呤组为1.3(SD 0.7)、NSAIDs组1.6(SD 0.9)、巴瑞替尼组1.7(SD 0.9),组间比较p=0.38,无显著差异。
- 研究期间所有治疗组严重不良事件发生率均保持较低。
关键数值与推荐
- 主要终点为3个月时DAS(44/53关节)改善,采用协方差分析校正基线DAS。
- 巴瑞替尼组3个月DAS校正平均变化-0.52(95%CI -0.93至-0.11;p=0.01)。
- 甲氨蝶呤组3个月DAS校正平均变化-0.39(95%CI -0.84至0.06;p=0.09)。
- 12个月DAS:甲氨蝶呤组1.3(SD 0.7)、NSAIDs组1.6(SD 0.9)、巴瑞替尼组1.7(SD 0.9),p=0.38。
临床怎么用
- 对于早期未分化关节炎患者,可考虑在糖皮质激素注射基础上早期使用DMARD以更快改善3个月疾病活动度。
- 巴瑞替尼在3个月疾病活动度改善方面显示出统计学显著优势,但12个月时各组结局趋同。
- 甲氨蝶呤3个月改善数值上接近巴瑞替尼但未达统计学显著,临床决策需结合患者具体情况。
局限性
- 研究为单盲设计,可能存在实施偏倚。
- 每组样本量较小(NSAIDs组29例、甲氨蝶呤组28例、巴瑞替尼组28例),可能影响统计效能。
- 12个月观察期数据非主要终点,组间比较未达显著可能受样本量限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate whether in undifferentiated arthritis (UA) it is beneficial to start early treatment with disease-modifying antirheumatic drugs (DMARDs) compared with symptomatic therapy. METHODS: The Induction of Cure in Early Arthritis study is a 3-month multicentre single-blinded randomised controlled trial followed by a 9-month observational period. Patients with early DMARD-naïve UA (arthritis ≥2 joints, not fulfilling American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) 2010 Rheumatoid Arthritis criteria) received a glucocorticoid injection (40 mg intra-articular or intramuscular) and were randomised (1:1:1) to a 3-month intervention with (1) non-steroidal anti-inflammatory drugs (NSAIDs) in standard daily dose or (2) methotrexate (MTX) 15 mg/week increased to 25 mg/week or (3) baricitinib 4 mg/day. Primary endpoint was Disease Activity Score (DAS) (44/53 joints) improvement at 3 months. Differences between treatment arms were assessed with analysis of covariance, adjusted for baseline DAS. RESULTS: Patients were randomised to NSAID (n=29), MTX (n=28) or baricitinib (n=28). After 3 months, baricitinib gave a significant improvement in DAS compared with NSAIDs: adjusted mean change in DAS: -0.52 (95% CI -0.93 to -0.11; p=0.01). MTX gave a numerically similar improvement: -0.39 (95% CI -0.84 to 0.06, p=0.09). Although non-significant, at 12 months DAS was lowest in the MTX treatment arm 1.3 (SD 0.7), NSAID 1.6 (SD 0.9), baricitinib 1.7 (SD 0.9), p=0.38. Incidence rates of severe adverse events remained low during the study across all treatment arms. CONCLUSIONS: In patients with UA, early DMARD treatment led to greater improvement in disease activity over 3 months compared with NSAIDs, with the improvement for baricitinib reaching statistical significance. Over 12 months, disease activity was not significantly different across treatment arms, with overall favourable outcomes.
引用
- Nevins IS, van der Pol JA, Van Ouwerkerk L, et al. Induction of Cure in Early Arthritis (I CEA): results of a randomised clinical trial to compare three treatment strategies in recent onset undifferentiated arthritis. RMD Open. 2026. PMID: 42209019. doi:10.1136/rmdopen-2026-006828
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。